Imatinib mesylate-induced psoriasiform drug reaction: A case of dose-dependent cutaneous toxicity

Imatinib mesylate-induced psoriasiform drug reaction: A case of dose-dependent cutaneous toxicity

Bibliographic Details
Main Authors:	Aditya Holani, Swapna Khatu, Rajvardhan Bagane, Aishwarya Bedi
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Indian Journal of Drugs in Dermatology
Online Access:	http://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=1;spage=46;epage=48;aulast=Holani

Similar Items

Imatinibe mesilato no Brasil Imatinibe mesylate in Brazil
by: Marcos Lima
Published: (2005-09-01)

Effects of imatinib mesylate on cutaneous neurofibromas associated with neurofibromatosis type 1
by: Ken‐ichi Yasuda, et al.
Published: (2020-11-01)

Imatinib mesylate-induced cutaneous rash masquerading as pityriasis rosea of Gilbert
by: Prashant Verma, et al.
Published: (2014-01-01)

A case of pediatric cutaneous mastocytosis successfully treated with imatinib mesylate
by: Rameshwar Gutte, et al.
Published: (2017-01-01)

Imatinib mesylate-induced palmoplantar keratoderma
by: Niharika Jha, et al.
Published: (2021-01-01)

Periorbital edema secondary to imatinib mesylate
by: Collin M McClelland, et al.
Published: (2010-05-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)

The teratogenic effects of imatinib mesylate on rat fetuses
by: M.M. El Gendy, et al.
Published: (2015-01-01)

Generalized lichenoid drug eruption associated with imatinib mesylate therapy
by: Sudip Kumar Ghosh
Published: (2013-01-01)

Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines
by: Kulkarni Hemant, et al.
Published: (2012-08-01)

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis
by: Ol'ga Veniaminovna Stakhina, et al.
Published: (2010-02-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Molecular Mobility and Stability Studies of Amorphous Imatinib Mesylate
by: Bożena Karolewicz, et al.
Published: (2019-07-01)

The role of c-kit and imatinib mesylate in uveal melanoma
by: Pereira Patricia, et al.
Published: (2005-10-01)

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
by: Omar S Din, et al.
Published: (2008-03-01)

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
by: Lori Rink, et al.
Published: (2013-01-01)

OUR EXPERIENCE WITH TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Mojca Modic, et al.
Published: (2004-12-01)

Anti-Diabetic and Beta-Cell Protective Actions of Imatinib Mesylate
by: Hägerkvist, Robert
Published: (2006)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

OUR EXPERIENCE IN TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB MESYLATE
by: Marjana Glaser, et al.
Published: (2004-04-01)

A first case of late-onset imatinib mesylate-induced lichenoid drug eruption
by: Farhana I Khan, et al.
Published: (2019-01-01)

Psoriasiform Eruption Secondary to PI3K-delta Inhibitor: Expanding the Spectrum of Psoriasiform Paradoxical Reactions?
by: David Pesqué, et al.
Published: (2021-03-01)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
by: Vijay Gandhi Linga, et al.
Published: (2014-01-01)

Effects of Imatinib Mesylate in Mouse Models of Multiple Sclerosis and In vitro Determinants
by: Gholamreza Azizi, et al.
Published: (2014-06-01)

Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia
by: Aamer Aleem
Published: (2009-04-01)

Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
by: Zheng Hu, et al.
Published: (2009-01-01)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
by: Ana Lucia Vieira-Mion, et al.

In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
by: Weigel Marion T, et al.
Published: (2010-08-01)

Psoriasiform paradojic reaction associated with infliximab infusion
by: Lorena De Agustín Sierra
Published: (2017-07-01)

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours
by: Lucy C. Scott, et al.
Published: (2005-01-01)

Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
by: Jing Liu, et al.
Published: (2017-03-01)

Successful Long-Term Control of the Syndrome of Episodic Angioedema With Eosinophilia (Gleich Syndrome) With Low-Dose Imatinib Mesylate and Prednisone
by: Joseph H. Butterfield MD
Published: (2021-01-01)

Column chromatography USED in purification of genotoxic impurity sample of imatinib mesylate substance
by: V. I. Krylov, et al.
Published: (2018-02-01)

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
by: Doran Ksienski
Published: (2011-11-01)

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
by: Doran Ksienski
Published: (2011-01-01)